A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial

Mike Dennis, Alan Burnett, Robert Hills, Ian Thomas, Cono Ariti, Marianne T. Severinsen, Claire Hemmaway, Paul Greaves, Richard E. Clark, Mhairi Copland, Nigel Russell, on behalf of the National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial'. Together they form a unique fingerprint.

Medicine and Dentistry